首页> 外文期刊>Molecular therapy: the journal of the American Society of Gene Therapy >Recombinant AAV as a platform for translating the therapeutic potential of RNA interference
【24h】

Recombinant AAV as a platform for translating the therapeutic potential of RNA interference

机译:重组AAV作为翻译RNA干扰治疗潜力的平台

获取原文
获取原文并翻译 | 示例
           

摘要

RNA interference has become a ubiquitous biological tool, and is being harnessed for therapeutic purposes as well. Therapeutic posttranscriptional gene silencing takes advantage of the endogenous RNAi pathway through delivery of either chemically synthesized siRNAs, or transgenes expressing hairpin-based inhibitory RNAs (e.g., shRNAs and artificial miRNAs). RNAi has expanded the field of viral gene therapy from gene replacement to gene knockdown. Here, we review various noncoding RNAs such as shRNAs, miRNAs, and miRNA decoys which can be utilized for therapeutic applications when expressed from recombinant adeno-associated vectors (AAV), and present examples of their basic design. In addition the basis of exploiting cellular miRNA profiles for detargeting AAV expression from specific cells is described. Finally, an overview of AAV-mediated RNAi preclinical studies is presented, and current RNAi-based clinical trials are reviewed.
机译:RNA干扰已成为一种普遍存在的生物学工具,并且也已被用于治疗目的。治疗性转录后基因沉默通过传递化学合成的siRNA或表达基于发夹的抑制性RNA的转基因(例如,shRNA和人工miRNA)来利用内源性RNAi途径。 RNAi已将病毒基因治疗的领域从基因替换扩展到基因敲除。在这里,我们综述了各种非编码RNA,例如shRNA,miRNA和miRNA诱饵,它们从重组腺相关载体(AAV)表达时可用于治疗应用,并提供了其基本设计实例。另外,描述了利用细胞miRNA谱用于使来自特定细胞的AAV表达脱靶的基础。最后,对AAV介导的RNAi临床前研究进行了概述,并对当前基于RNAi的临床试验进行了综述。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号